Can a white blood cell booster heal a rare skin emergency?
NCT ID NCT02739295
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether G-CSF (a drug that boosts white blood cells) can help heal toxic epidermal necrolysis, a rare but severe skin reaction. Ten patients were randomly assigned to receive G-CSF or a placebo for five days. Researchers measured how fast the skin healed and looked at immune cell changes in the skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
G-CSF (Neupogen)
What this could lead to
If it works, G-CSF could speed up skin healing and improve outcomes for people with this rare, life-threatening skin condition.
What could go wrong
This is a very small trial (10 people) and results may not apply to all patients. G-CSF can cause side effects like bone pain or spleen enlargement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEVENS-JOHNSON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Burn Centre of the University Hospital of Liège
Liège, 4000, Belgium
-
IMTR Burn Centre
Loverval, Belgium